AhR-mediated, non-genomic modulation of IDO1 function

Frontiers in Immunology

Volumn 5, Issue OCT, 2014, Pages

  Pallotta, Maria Teresa ^a   Fallarino, Francesca ^a   Matino, Davide ^a   Macchiarulo, Antonio ^a   Orabona, Ciriana ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

AhR; Dendritic cells; IDO1; Immunoregulation; ITIM; L kynurenine; Tryptophan metabolism; Ubiquitin ligase complex

Indexed keywords

ANDROGEN RECEPTOR; AROMATIC HYDROCARBON RECEPTOR; BETA CATENIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ESTROGEN RECEPTOR; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INTERLEUKIN 6; KYNURENINE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CATABOLISM; ENZYME ACTIVITY; GENE EXPRESSION; HALF LIFE TIME; HUMAN; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; IMMUNOREGULATION; INTRACELLULAR SIGNALING; MOLECULAR DOCKING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

EID: 84918842254     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00497     Document Type: Article

References (45)

1. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 281:1191-3. doi: 10.1126/science.281.5380.1191
2. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol (2007) 7:817-23. doi:10.1038/nri2163
3. Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, et al. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A (2008) 105:20828-33. doi:10.1073/pnas.0810278105
4. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 12:870-8. doi:10.1038/ni.2077
5. Orabona C, Pallotta MT, Grohmann U. Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol Med (2012) 18:834-42. doi:10.2119/molmed.2012.00029
6. Stevens EA, Mezrich JD, Bradfield CA. The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology (2009) 127:299-311. doi:10.1111/j.1365-2567.2009.03054.x
7. Poellinger L. Mechanistic aspects - the dioxin (aryl hydrocarbon) receptor. Food Addit Contam (2000) 17:261-6. doi:10.1080/026520300283333
8. Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol (1995) 35:307-40. doi:10.1146/annurev.pa.35.040195.001515
9. Matsumura F, Vogel CF. Evidence supporting the hypothesis that one of the main functions of the aryl hydrocarbon receptor is mediation of cell stress responses. Biol Chem (2006) 387:1189-94. doi:10.1515/BC.2006.146
10. Mimura J, Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta (2003) 1619:263-8. doi:10.1016/S0304-4165(02)00485-3
11. Dinatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM, et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci (2010) 115:89-97. doi:10.1093/toxsci/kfq024
12. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol (2010) 185:3190-8. doi:10.4049/jimmunol.0903670
13. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature (2014) 511:184-90. doi:10.1038/nature13323
14. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H, et al. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature (2007) 446:562-6. doi:10.1038/nature05683
15. Ohtake F, Fujii-Kuriyama Y, Kato S. AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochem Pharmacol (2009) 77:474-84. doi:10.1016/j.bcp.2008.08.034
16. Kawajiri K, Kobayashi Y, Ohtake F, Ikuta T, Matsushima Y, Mimura J, et al. Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc Natl Acad Sci U S A (2009) 106:13481-6. doi:10.1073/pnas.0902132106
17. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell (1994) 78:761-71. doi:10.1016/S0092-8674(94)90462-6
18. Sugimoto H, Oda S, Otsuki T, Hino T, Yoshida T, Shiro Y. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci U S A (2006) 103:2611-6. doi:10.1073/pnas.0508996103
19. Cannon WR, Benkovic SJ. Solvation, reorganization energy, and biological catalysis. J Biol Chem (1998) 273:26257-60. doi:10.1074/jbc.273.41.26257
20. Benkovic SJ, Hammes GG, Hammes-Schiffer S. Free-energy landscape of enzyme catalysis. Biochemistry (2008) 47:3317-21. doi:10.1021/bi800049z
21. Bahar I, Chennubhotla C, Tobi D. Intrinsic dynamics of enzymes in the unbound state and relation to allosteric regulation. Curr Opin Struct Biol (2007) 17:633-40. doi:10.1016/j.sbi.2007.09.011
22. Orr SJ, Morgan NM, Buick RJ, Boyd CR, Elliott J, Burrows JF, et al. SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses. J Biol Chem (2007) 282:3418-22. doi:10.1074/jbc.C600216200
23. Orr SJ, Morgan NM, Elliott J, Burrows JF, Scott CJ, McVicar DW, et al. CD33 responses are blocked by SOCS3 through accelerated proteasomal- mediated turnover. Blood (2007) 109:1061-8. doi:10.1182/blood-2006-05-023556
24. Orabona C, Belladonna M, Vacca C, Bianchi R, Fallarino F, Volpi C, et al. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol (2005) 174:6582-6. doi:10.4049/jimmunol.174.11.6582
25. Orabona C, Grohmann U, Belladonna ML, Fallarino F, Vacca C, Bianchi R, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol (2004) 5:1134-42. doi:10.1038/ni1124
26. Pallotta MT, Orabona C, Volpi C, Grohmann U, Puccetti P, Fallarino F. Proteasomal degradation of indoleamine 2,3-dioxygenase in CD8 dendritic cells is mediated by suppressor of cytokine signaling 3 (SOCS3). Int J Tryptophan Res (2010) 3:91-7. doi:10.4137/IJTR.S3971
27. Tian Y. Ah receptor and NF-kappaB interplay on the stage of epigenome. Biochem Pharmacol (2009) 77:670-80. doi:10.1016/j.bcp.2008.10.023
28. Ohtake F, Baba A, Fujii-Kuriyama Y, Kato S. Intrinsic AhR function underlies cross-talk of dioxins with sex hormone signalings. Biochem Biophys Res Commun (2008) 370:541-6. doi:10.1016/j.bbrc.2008.03.054
29. Mcberry C, Gonzalez RM, Shryock N, Dias A, Aliberti J. SOCS2-induced proteasome-dependent TRAF6 degradation: a common anti-inflammatory pathway for control of innate immune responses. PLoS One (2012) 7:e38384. doi:10.1371/journal.pone.0038384
30. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol (2003) 24:242-8. doi:10.1016/S1471-4906(03)00072-3
31. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A (2010) 107:19961-6. doi:10.1073/pnas.1014465107
32. Hao K, Zhou Q, Chen W, Jia W, Zheng J, Kang J, et al. Possible role of the 'IDO-AhR axis' in maternal-foetal tolerance. Cell Biol Int (2013) 37:105-8. doi:10.1002/cbin.10023
33. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget (2014) 5:1038-51.
34. Vogel CF, Wu D, Goth SR, Baek J, Lollies A, Domhardt R, et al. Aryl hydrocarbon receptor signaling regulates NF-kappaB RelB activation during dendritic-cell differentiation. Immunol Cell Biol (2013) 91:568-75. doi:10.1038/icb.2013.43
35. Dong B, Matsumura F. Roles of cytosolic phospholipase A2 and Src kinase in the early action of 2,3,7,8-tetrachlorodibenzo-p-dioxin through a nongenomic pathway in MCF10A cells. Mol Pharmacol (2008) 74:255-63. doi:10.1124/mol.107.044669
36. Park S, Mazina O, Kitagawa A, Wong P, Matsumura F. TCDD causes suppression of growth and differentiation of MCF10A, human mammary epithelial cells by interfering with their insulin receptor signaling through c-Src kinase and ERK activation. J Biochem Mol Toxicol (2004) 18:322-31. doi:10.1002/jbt.20040
37. Mazina O, Park S, Sano H, Wong P, Matsumura F. Studies on the mechanism of rapid activation of protein tyrosine phosphorylation activities, particularly c-Src kinase, by TCDD in MCF10A. J Biochem Mol Toxicol (2004) 18:313-21. doi:10.1002/jbt.20041
38. De Luca A, Carvalho A, Cunha C, Iannitti RG, Pitzurra L, Giovannini G, et al. IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis. PLoS Pathog (2013) 9:e1003486. doi:10.1371/journal.ppat.1003486
39. Brant F, Miranda AS, Esper L, Rodrigues DH, Kangussu LM, Bonaventura D, et al. Immune response profile and development of pathology during Plasmodium berghei Anka infection: the role of the aryl hydrocarbon receptor (AhR). Infect Immun (2014) 82(8):3127-40. doi:10.1128/IAI.01733-14
40. Morales JL, Perdew GH. Carboxyl terminus of hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR) complexes and mediate ubiquitination of both the AhR and the 90 kDa heat-shock protein (hsp90) in vitro. Biochemistry (2007) 46:610-21. doi:10.1021/bi062165b
41. Ohtake F, Fujii-Kuriyama Y, Kawajiri K, Kato S. Cross-talk of dioxin and estrogen receptor signals through the ubiquitin system. J Steroid Biochem Mol Biol (2011) 127:102-7. doi:10.1016/j.jsbmb.2011.03.007
42. Hanafi LA, Gauchat D, Godin-Ethier J, Possamai D, Duvignaud JB, Leclerc D, et al. Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism. PLoS One (2014) 9:e99211. doi:10.1371/journal.pone.0099211
43. Levina V, Su Y, Gorelik E. Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation. Clin Dev Immunol (2012) 2012:173029. doi:10.1155/2012/173029
44. Mei J, Li MQ, Ding D, Li DJ, Jin LP, Hu WG, et al. Indoleamine 2,3-dioxygenase-1 (IDO1) enhances survival and invasiveness of endometrial stromal cells via the activation of JNK signaling pathway. Int J Clin Exp Pathol (2013) 6:431-44.
45. Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. J Clin Endocrinol Metab (2014) 99:E832-40. doi:10.1210/jc.2013-3351